Dopamine D3 receptor as a new pharmacological target for the treatment of depression

Gian Marco Leggio, Salvatore Salomone, Claudio Bucolo, Chiara Platania, Vincenzo Micale, Filippo Caraci, Filippo Drago

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

A substantial proportion of depressed patients do not respond to current antidepressant drug therapies. So far, antidepressant drugs have been developed based on the "monoaminergic hypothesis" of depression, which considers a synaptic deficiency in 5-hydroxytryptamine (5-HT; serotonin) or noradrenaline as main cause. More recently, the dopaminergic system has been implicated in the efficacy of some antidepressants, such as desipramine, amineptine, nomifensine. Dysfunction of dopaminergic neurotransmission within the mesolimbic system may contribute to anhedonia, loss of motivation and psychomotor retardation in severe depressive disorders. Dopamine D3 receptor subtype is located both pre- and postsynaptically in brain areas regulating motivation and reward-related behavior and has been implicated in depression-like behaviors. Activity of mesolimbic dopamine neurons in the reward circuit is a key determinant of behavioral susceptibility/resilience to chronic stress, which plays a central role in the pathogenesis of depression. Dopamine D3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine D3 receptor participates in adaptive changes related to antidepressant activity. Of note, brain derived neurotrophic factor (BDNF) controls the expression of the dopamine D3 receptor in some brain areas and BDNF induction by antidepressant treatments is related to their behavioral activity. A number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine D3 receptors. These preclinical and clinical data are discussed in the present review.

Original languageEnglish
Pages (from-to)25-33
Number of pages9
JournalEuropean Journal of Pharmacology
Volume719
Issue number1-3
DOIs
Publication statusPublished - 2013

Fingerprint

Dopamine D3 Receptors
Antidepressive Agents
Pharmacology
Depression
Serotonin
Brain-Derived Neurotrophic Factor
amineptin
Reward
Synaptic Transmission
Therapeutics
Motivation
Nomifensine
Anhedonia
Desipramine
Dopaminergic Neurons
Brain
Depressive Disorder
Norepinephrine
Drug Therapy

Keywords

  • Aripiprazole
  • Brain-derived neurotrophic factor
  • Depression
  • Dopamine D receptor
  • Partial agonist
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dopamine D3 receptor as a new pharmacological target for the treatment of depression. / Leggio, Gian Marco; Salomone, Salvatore; Bucolo, Claudio; Platania, Chiara; Micale, Vincenzo; Caraci, Filippo; Drago, Filippo.

In: European Journal of Pharmacology, Vol. 719, No. 1-3, 2013, p. 25-33.

Research output: Contribution to journalArticle

Leggio, Gian Marco ; Salomone, Salvatore ; Bucolo, Claudio ; Platania, Chiara ; Micale, Vincenzo ; Caraci, Filippo ; Drago, Filippo. / Dopamine D3 receptor as a new pharmacological target for the treatment of depression. In: European Journal of Pharmacology. 2013 ; Vol. 719, No. 1-3. pp. 25-33.
@article{3d0c2afcc3fa4276af0e7f126ce95fdf,
title = "Dopamine D3 receptor as a new pharmacological target for the treatment of depression",
abstract = "A substantial proportion of depressed patients do not respond to current antidepressant drug therapies. So far, antidepressant drugs have been developed based on the {"}monoaminergic hypothesis{"} of depression, which considers a synaptic deficiency in 5-hydroxytryptamine (5-HT; serotonin) or noradrenaline as main cause. More recently, the dopaminergic system has been implicated in the efficacy of some antidepressants, such as desipramine, amineptine, nomifensine. Dysfunction of dopaminergic neurotransmission within the mesolimbic system may contribute to anhedonia, loss of motivation and psychomotor retardation in severe depressive disorders. Dopamine D3 receptor subtype is located both pre- and postsynaptically in brain areas regulating motivation and reward-related behavior and has been implicated in depression-like behaviors. Activity of mesolimbic dopamine neurons in the reward circuit is a key determinant of behavioral susceptibility/resilience to chronic stress, which plays a central role in the pathogenesis of depression. Dopamine D3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine D3 receptor participates in adaptive changes related to antidepressant activity. Of note, brain derived neurotrophic factor (BDNF) controls the expression of the dopamine D3 receptor in some brain areas and BDNF induction by antidepressant treatments is related to their behavioral activity. A number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine D3 receptors. These preclinical and clinical data are discussed in the present review.",
keywords = "Aripiprazole, Brain-derived neurotrophic factor, Depression, Dopamine D receptor, Partial agonist, Treatment-resistant depression",
author = "Leggio, {Gian Marco} and Salvatore Salomone and Claudio Bucolo and Chiara Platania and Vincenzo Micale and Filippo Caraci and Filippo Drago",
year = "2013",
doi = "10.1016/j.ejphar.2013.07.022",
language = "English",
volume = "719",
pages = "25--33",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Dopamine D3 receptor as a new pharmacological target for the treatment of depression

AU - Leggio, Gian Marco

AU - Salomone, Salvatore

AU - Bucolo, Claudio

AU - Platania, Chiara

AU - Micale, Vincenzo

AU - Caraci, Filippo

AU - Drago, Filippo

PY - 2013

Y1 - 2013

N2 - A substantial proportion of depressed patients do not respond to current antidepressant drug therapies. So far, antidepressant drugs have been developed based on the "monoaminergic hypothesis" of depression, which considers a synaptic deficiency in 5-hydroxytryptamine (5-HT; serotonin) or noradrenaline as main cause. More recently, the dopaminergic system has been implicated in the efficacy of some antidepressants, such as desipramine, amineptine, nomifensine. Dysfunction of dopaminergic neurotransmission within the mesolimbic system may contribute to anhedonia, loss of motivation and psychomotor retardation in severe depressive disorders. Dopamine D3 receptor subtype is located both pre- and postsynaptically in brain areas regulating motivation and reward-related behavior and has been implicated in depression-like behaviors. Activity of mesolimbic dopamine neurons in the reward circuit is a key determinant of behavioral susceptibility/resilience to chronic stress, which plays a central role in the pathogenesis of depression. Dopamine D3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine D3 receptor participates in adaptive changes related to antidepressant activity. Of note, brain derived neurotrophic factor (BDNF) controls the expression of the dopamine D3 receptor in some brain areas and BDNF induction by antidepressant treatments is related to their behavioral activity. A number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine D3 receptors. These preclinical and clinical data are discussed in the present review.

AB - A substantial proportion of depressed patients do not respond to current antidepressant drug therapies. So far, antidepressant drugs have been developed based on the "monoaminergic hypothesis" of depression, which considers a synaptic deficiency in 5-hydroxytryptamine (5-HT; serotonin) or noradrenaline as main cause. More recently, the dopaminergic system has been implicated in the efficacy of some antidepressants, such as desipramine, amineptine, nomifensine. Dysfunction of dopaminergic neurotransmission within the mesolimbic system may contribute to anhedonia, loss of motivation and psychomotor retardation in severe depressive disorders. Dopamine D3 receptor subtype is located both pre- and postsynaptically in brain areas regulating motivation and reward-related behavior and has been implicated in depression-like behaviors. Activity of mesolimbic dopamine neurons in the reward circuit is a key determinant of behavioral susceptibility/resilience to chronic stress, which plays a central role in the pathogenesis of depression. Dopamine D3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine D3 receptor participates in adaptive changes related to antidepressant activity. Of note, brain derived neurotrophic factor (BDNF) controls the expression of the dopamine D3 receptor in some brain areas and BDNF induction by antidepressant treatments is related to their behavioral activity. A number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine D3 receptors. These preclinical and clinical data are discussed in the present review.

KW - Aripiprazole

KW - Brain-derived neurotrophic factor

KW - Depression

KW - Dopamine D receptor

KW - Partial agonist

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=84888286535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888286535&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2013.07.022

DO - 10.1016/j.ejphar.2013.07.022

M3 - Article

C2 - 23872400

AN - SCOPUS:84888286535

VL - 719

SP - 25

EP - 33

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -